Effect of clopidogrel on bleeding after coronary artery bypass surgery

Area of Science:

• Cardiology
• Cardiovascular Surgery
• Pharmacology

Background:

• Platelet dysfunction is a significant cause of bleeding post-coronary artery bypass graft (CABG) surgery.
• Understanding the impact of antiplatelet agents like clopidogrel on surgical bleeding is crucial for patient safety.

Purpose of the Study:

• To investigate the association between preoperative clopidogrel use and bleeding complications following CABG surgery.
• To evaluate the effect of clopidogrel on the need for reexploration and blood product transfusions after CABG.

Main Methods:

• Prospective observational study conducted at a tertiary care center.
• 247 patients undergoing coronary artery bypass graft surgery were included.
• Outcomes measured included reexploration for bleeding, transfusion of packed red blood cells, cryoprecipitate, platelets, and fresh frozen plasma.

Main Results:

• Eight patients (3.3%) required reexploration due to bleeding.
• Clopidogrel use was associated with a significantly higher incidence of reexploration (9.8% vs. 1.6%, p=0.01).
• Clopidogrel recipients showed increased requirements for packed red blood cell (72.6% vs. 51.6%) and cryoprecipitate transfusions (2.4 vs. 1.2 units).

Conclusions:

• Preoperative clopidogrel, when used with aspirin, is linked to a greater need for surgical reexploration after CABG.
• The use of clopidogrel increases the risk of requiring packed red blood cell and cryoprecipitate transfusions post-CABG.
• These findings highlight potential risks associated with clopidogrel use in patients undergoing CABG surgery.